Charles River Laboratories | CRL - Pre Tax Profit


Charles River Laboratories reported $-294.1M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Agilent USD 364M 78M Dec/2025
Align Technology USD 148.89M 27.71M Mar/2026
Bio-Rad Laboratories USD 929.2M 846.3M Dec/2025
Bruker USD 68.2M 140.8M Dec/2025
Cardinal Health USD 630M 32M Dec/2025
Charles River Laboratories USD -294.1M 464.13M Dec/2025
Cigna USD 1.82B 478M Dec/2025
CVS Health USD 3.94B 2.58B Mar/2026
Danaher USD 1.24B 138M Mar/2026
Dentsply International USD -42M 105M Mar/2026
Elevance Health USD 2.16B 146M Jun/2026
Humana USD -1.01B 1.54B Dec/2025
Illumina USD 157M 220M Mar/2026
Incyte USD 343.6M 46.34M Mar/2026
Intrexon USD -60.48M 27.09M Jun/2024
IQVIA Holdings USD 6.22B 5.68B Mar/2026
Laboratory Of America USD 8.73B 8.54B Mar/2026
Lakefront Biotherapeutics EUR 13.96M 769.2M Mar/2026
Lonza CHF 624M 197M Dec/2024
McKesson USD 1.63B 235M Dec/2025
Merck EUR 401M 886.1M Dec/2025
Mettler Toledo International USD 329.07M 59.84M Dec/2025
Novartis USD 3.84B 802M Mar/2026
Pfizer USD 5.18B 6.82B Mar/2026
Quest Diagnostics USD 334M 4M Mar/2026
Revvity USD 91.56M 35.88M Dec/2025
Thermo Fisher Scientific USD 2.12B 295M Dec/2025
United Therapeutics USD 444M 6M Dec/2025
UnitedHealth USD 7.36B 600M Jun/2026
Veradigm USD 35.3M 13.95M Sep/2022
Waters USD 264.18M 94.06M Dec/2025
West Pharmaceutical Services USD 161.5M 8.6M Dec/2025